Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).

BMC Cancer · 2024 · PMC10885390 · PMID 38395832

Europe PMC DOI

hedged sentence

0.0990

closest p · 2.0× alpha

0.0990

boldest claim

The sentences

showed a trendp = 0.099so close (0.05 < p ≤ 0.1)

Although not statistically significant in subgroup analyses, patients without peritoneal metastasis showed a trend of better PFS with ICI than irinotecan-based chemotherapy [HR 0.68 (95% CI, 0.42–1.08); p = 0.099).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.